Novo Nordisk A/S (NYSE:NVO) Sets New 52-Week Low Following Analyst Downgrade

Novo Nordisk A/S (NYSE:NVO) shares hit a new 52-week low on Monday after Kepler Capital Markets downgraded the stock from a buy rating to a hold rating. The stock traded as low as $40.01 and last traded at $41.0070, with a volume of 5989976 shares. The stock had previously closed at $47.42.

Several other analysts have also commented on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. CICC Research started coverage on Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price on the stock. Morgan Stanley reissued an “underweight” rating and set a $42.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday. Finally, Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. Six investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $56.07.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Phase‑2 China trial: a joint Novo program (UBT251, a triple GLP‑1/GIP/glucagon agonist) reported up to ~19.7% mean weight loss at 24 weeks with a tolerable safety profile — a constructive signal for long‑term pipeline diversification beyond semaglutide. UBT251 Phase 2 China results
• Neutral Sentiment: Some investors and bullish analysts argue the market is overreacting to a single head‑to‑head miss and point to continued Wegovy/Ozempic international growth and upcoming oral options as offsetting factors. Seeking Alpha perspective
• Negative Sentiment: REDEFINE‑4 Phase‑3 miss: CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide in an open‑label head‑to‑head, raising doubts about Novo’s ability to defend obesity market share against Lilly’s lead. This clinical setback is the primary catalyst for the recent sell‑off. CagriSema trial coverage
• Negative Sentiment: Price cuts: Novo announced plans to reduce U.S. list prices for Wegovy and Ozempic (up to ~50%, with headline pricing around $675/month starting Jan 2027), a move intended to improve access but likely to pressure list‑price revenue and margins. Price cut report
• Negative Sentiment: Analyst reactions and downgrades: multiple banks trimmed ratings/targets after the trial news, and coverage turned more cautious — amplifying selling pressure and repricing expectations for growth. Analyst downgrades coverage
• Negative Sentiment: Legal/investor scrutiny: law‑firm notices and investor inquiries have appeared following the clinical disclosure, representing an added reputational and potential financial overhang. Investor investigation notice

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC grew its stake in shares of Novo Nordisk A/S by 0.3% during the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after buying an additional 63,341 shares during the period. Capital International Investors grew its position in Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares during the period. Loomis Sayles & Co. L P grew its position in Novo Nordisk A/S by 6.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares during the period. Franklin Resources Inc. increased its stake in Novo Nordisk A/S by 5.1% during the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after acquiring an additional 717,719 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Novo Nordisk A/S by 3.5% in the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after purchasing an additional 428,660 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.5%

The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $172.52 billion, a price-to-earnings ratio of 11.13 and a beta of 0.67. The firm has a 50 day moving average price of $53.35 and a two-hundred day moving average price of $53.14.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.